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tTo the Editor: Transcatheter closure of perimembranous ventricular
septal defects (pmVSD) is a well-established procedure but is
associated with an unacceptable incidence of complete heart block
(CHB) (1,2). We describe retrograde single catheter closure of
pmVSDs by an off-label use of the Amplatzer duct occluder II
(ADO II) device (St. Jude Medical, St. Paul, Minnesota).
All children between 1 and 15 years with pmVSD were included
in the initial assessment. The decision to use the ADO II device
was based primarily on reduction of the cost of the procedure
($1,500 for device closure) and the need to close symptomatic
VSDs in young patients.
Clinical inclusion criteria: At least 3 of the following had to be
present:
Overt heart failure, not improving with medications
Failure to thrive, predominantly due to hemodynamic effects of
the VSD
Recurrent respiratory infections (defined as 6 events in the
preceding 12 months)
Mid-diastolic flow rumble at the apex on auscultation
Electrocardiogram showing left atrial enlargement and left
ventricular hypertrophy with standard criteria for children
Cardiothoracic ratio on chest x-ray of 0.55
Left atrial to aortic diameter ratio on long-axis echocardiogram
1.5
Left ventricular end-diastolic z-score on echocardiogram, in-
dexed to body surface area of 2.0
Estimated pulmonary to systemic blood flow ratio 1.5 at
cardiac catheterization
Morphologic inclusion criteria:
Isolated pmVSD
VSD size 6.5 mm
Upper margin of VSD to aortic valve distance  3 mm
Morphologic exclusion criteria:
VSD size 6.5 mm
Perimembranous VSD with bidirectional or predominantly
right to left shunt through the VSD on color Doppler echocar-
diography
Perimembranous VSD associated with other structural heart
defects requiring surgery
Cardiac catheterization was performed under general anesthesia
(n  12) or intravenous sedation (n  51), after informed consent
was obtained. Intravenous heparin (100 U/kg) was given after
femoral arterial access was obtained. Procedures were monitored
by transthoracic echocardiography. The diameter of the device is
chosen to be either equal to (0.5 mm) or 1 mm greater than the
smallest VSD diameter. A 5-F (internal diameter 0.061 inch) or
6-F (internal diameter 0.070 inch) right coronary artery guidingcatheter with side holes (Launcher, Medtronic, Minneapolis,
Minnesota; or Cordis, Cordis, Miami Lakes, Florida) was used as
the delivery catheter, via the femoral artery. A 0.035-inch or
0.032-inch angulated hydrophilic guidewire (Terumo Corpora-
tion, Tokyo, Japan) was used to cross the VSD. The guide catheter
was then advanced over the wire into the right ventricle. In a few
cases where the delivery catheter took a tortuous course, it was
stabilized in the right ventricle by the use of a 0.014-inch “buddy
wire” (Galeo Extra Support, Biotronik, Berlin, Germany; or Road
Runner, Cook, Inc., Bloomington, Indiana). Where multiple
openings were present at 6 mm distance from one another, the
procedure was either abandoned (n  2) or an additional device
was used (n  1) (Fig. 1). All children were given aspirin 3 to 5
mg/kg and clopidogrel 1 mg/kg for 6 months.
Of 63 patients initially assessed (31 male), 57 were eligible for
the procedure after left ventricular angiography. Their age ranged
from 0.7 to 14.5 years (median 3.7 years), and weight ranged from
7.0 to 31 kg (median 12.5 kg). Median fluoroscopic time was 8.8
(4.0 to 36) min. The median VSD diameter was 5 (3.4 to 6.5) mm.
Devices used (device diameter/length in mm) were 4/4 (n  3),
5/4 (n  21), 5/6 (n  3), 6/4 (n  29), and 6/6 (n  1). The
omplete VSD closure rate was 78% immediately after the proce-
ure as documented by left ventricular angiography and transtho-
acic echocardiography, 92% at 24 h, and 94% at last follow-up.
here was 1 device embolization to the pulmonary artery (6/4 mm
evice), 2 h after the procedure. The device was successfully
etrieved, and the defect was successfully closed with a 10-mm
mplatzer muscular VSD occluder. There was no incidence of
emoral pulse loss. Fifteen children had tricuspid regurgitation
TR) before the procedure. A reduction of pre-existing TR by at
east 2 grades was seen in 11 children after VSD closure; in the
ther 4 children it was converted to a normotensive (normal
alculated RV systolic pressure) TR. Two children developed new
rivial aortic regurgitation (AR). One boy who had pre-existing
R associated with valve cusp prolapse underwent device closure
ith abolition of AR. There was no incidence of left bundle branch
lock, P-Q prolongation, or CHB during the follow-up evalua-
ion. Most children (n  46) were underweight before the
procedure (less than the third centile for age and sex) and
demonstrated appropriate weight gain (with 38 of 45 children—
who were followed up for longer than 6 months after VSD
closure—reaching weights 10th centile) at follow-up.
Most procedure-related complications have occurred in patients
of 6 years of age and/ or weighing 15 kg (3). Post-procedure
CHB has been reported to occur in up to 18% of patients
undergoing transcatheter closure of a pmVSD under the age of 3
years (4). The longer central waist of the ADO II might avoid
mechanical compression of the peri-nodal tissue. The VSDs larger
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the retention discs are symmetrical, a minimum distance of 3 mm
is required between the upper margin of the VSD and the aortic
Figure 1 Membranous Septal Aneurysm With Multiple Fenestrations
See arrows, top left panel. A 0.014-inch guidewire in the pulmonary artery
(arrow, top right panel) is used to stabilize the delivery catheter during device
deployment. A significant residual shunt (stippled arrow, lower left panel) is
seen, which was closed with a second device (lower right panel). ADO II 
Amplatzer duct occluder II (St. Jude Medical, St. Paul, Minnesota).valve. The ADO II device is cheap and effective for closing
When Enthusiasm Meets Reality in Real-Lif
RDN (5). The exact proportion of patients eligible for RDN withpmVSDs. Availability of larger-sized ADO II devices might
increase its applicability, allowing percutaneous closure of a wider
range of VSDs.
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Eligibility for Renal Denervation
in Patients With Resistant Hypertensione PatientsTo the Editor: Percutaneous renal sympathetic denervation (RDN)
by radiofrequency ablation is a novel therapeutic intervention that
has been shown to decrease blood pressure (BP) significantly (1)
and persistently (2) in patients with resistant hypertension (RH).
However, the evidence supporting the use of this technique was
obtained in a single randomized controlled open trial including
106 patients (1) that has been subject to methodological criticism
(3,4). This led the European Society of Hypertension (ESH) to
release a position paper that defined strict eligibility criteria forthe only device currently available (Symplicity, Medtronic, Min-
neapolis, Minnesota) in “real-life conditions” remains unknown.
However, 36 of the 190 patients screened in the Symplicity
HTN-2 (Renal Denervation in Patients With Uncontrolled Hy-
pertension) trial (1) did not meet the BP criteria for inclusion, and
30 had a renal artery anatomy incompatible with RDN.
Therefore, we estimated the number of patients eligible for
RDN by retrospectively reviewing the computerized medical
records of all consecutive patients hospitalized for at least 1 day in
2011 at our tertiary hypertension center at a university hospital in
